Cardiff Oncology logo

Cardiff OncologyNASDAQ: CRDF

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 July 2004

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$125.79 M
-59%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector
-42%vs. 3y high
63%vs. sector
182.57
-79%vs. 3y high
97%vs. sector

Price

after hours | 95 min ago
$2.46-$0.11(-4.28%)

Dividend

No data over the past 3 years
$165.00 K$37.50 K
$165.00 K-$11.86 M

Analysts recommendations

Institutional Ownership

CRDF Latest News

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
globenewswire.com30 October 2024 Sentiment: POSITIVE

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
seekingalpha.com12 August 2024 Sentiment: POSITIVE

Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: POSITIVE

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

Cardiff Oncology to Present at the Jefferies Healthcare Conference
globenewswire.com29 May 2024 Sentiment: POSITIVE

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Seeking Alpha03 May 2024 Sentiment: POSITIVE

Cardiff Oncology, Inc. (NASDAQ: CRDF) Q1 2024 Results Earnings Conference Call will take place on May 2, 2024 at 4:30 PM ET. The call will be led by Kiki Patel from Investor Relations at Gilmartin Group, with Mark Erlander as CEO and Jamie Levine as CFO. Conference Call Participants include Mark Frahm from TD Cowen, Joseph Catanzaro from Piper Sandler, and Andy Hsieh from William Blair. Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research02 May 2024 Sentiment: POSITIVE

Cardiff Oncology (CRDF) reported a quarterly loss of $0.22 per share, which was better than the expected loss of $0.25 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.25 per share in the same quarter last year.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
GlobeNewsWire25 April 2024 Sentiment: NEUTRAL

Management will host a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT.

Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research01 April 2024 Sentiment: POSITIVE

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What type of business is Cardiff Oncology?

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

What sector is Cardiff Oncology in?

Cardiff Oncology is in the Healthcare sector

What industry is Cardiff Oncology in?

Cardiff Oncology is in the Biotechnology industry

What country is Cardiff Oncology from?

Cardiff Oncology is headquartered in United States

When did Cardiff Oncology go public?

Cardiff Oncology initial public offering (IPO) was on 27 July 2004

What is Cardiff Oncology website?

https://www.cardiffoncology.com

Is Cardiff Oncology in the S&P 500?

No, Cardiff Oncology is not included in the S&P 500 index

Is Cardiff Oncology in the NASDAQ 100?

No, Cardiff Oncology is not included in the NASDAQ 100 index

Is Cardiff Oncology in the Dow Jones?

No, Cardiff Oncology is not included in the Dow Jones index

When was Cardiff Oncology the previous earnings report?

No data

When does Cardiff Oncology earnings report?

The next expected earnings date for Cardiff Oncology is 28 February 2025